CpG oligodeoxynucleotide induces apoptosis and cell cycle arrest in A20 lymphoma cells via TLR9-mediated pathways

Molecular Immunology

Volumn 54, Issue 3-4, 2013, Pages 327-337

  Qi, Xu Feng ^a   Zheng, Li ^b   Kim, Cheol Su ^c   Lee, Kyu Jae ^c   Kim, Dong Heui ^c   Cai, Dong Qing ^a   Qin, Jun Wen ^a   Yu, Yan Hong ^a   Wu, Zheng ^a   Kim, Soo Ki ^c  

^a JINAN UNIVERSITY   (China)

^b GUANGDONG UNIVERSITY OF TECHNOLOGY   (China)

^c Yonsei University Wonju College of Medicine   (South Korea)

Author keywords

Apoptosis; B lymphoma cells; Cell cycle; Cytotoxicity; KSK CpG

Indexed keywords

CASPASE 3; CD9 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; TOLL LIKE RECEPTOR 9;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DNA FRAGMENTATION; ENZYME ACTIVITY; FLOW CYTOMETRY; LYMPHOMA CELL LINE; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P27; G1 PHASE; INTERFERON-GAMMA; LYMPHOMA; MAP KINASE SIGNALING SYSTEM; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; OLIGODEOXYRIBONUCLEOTIDES; POLY(ADP-RIBOSE) POLYMERASES; TOLL-LIKE RECEPTOR 9;

EID: 84873836826     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2013.01.001     Document Type: Article

References (36)

1. Benekli M., Baer M.R., Baumann H., Wetzler M. Signal transducer and activator of transcription proteins in leukemias. Blood 2003, 101:2940-2954.
2. Betting D.J., Yamada R.E., Kafi K., Said J., van Rooijen N., Timmerman J.M. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma. Journal of Immunotherapy 2009, 32:622-631.
3. Capitani N., Baldari C.T. The Bcl-2 family as a rational target for the treatment of B-cell chronic lymphocytic leukaemia. Current Medicinal Chemistry 2010, 17:801-811.
4. Chanan-Khan A., Porter C.W. Immunomodulating drugs for chronic lymphocytic leukaemia. Lancet Oncology 2006, 7:480-488.
5. Cheng M., Sexl V., Sherr C.J., Roussel M.F. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proceedings of the National Academy of Sciences of the United States of America 1998, 95:1091-1096.
6. Cho H.C., Kim B.H., Kim K., Park J.Y., Chang J.H., Kim S.K. Cancer immunotherapeutic effects of novel CpG ODN in murine tumor model. International Immunopharmacology 2008, 8:1401-1407.
7. Deveraux Q.L., Roy N., Stennicke H.R., Van Arsdale T., Zhou Q., Srinivasula S.M. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO Journal 1998, 17:2215-2223.
8. El Andaloussi A., Sonabend A.M., Han Y., Lesniak M.S. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia 2006, 54:526-535.
9. Friedberg J.W., Kim H., McCauley M., Hessel E.M., Sims P., Fisher D.C., Nadler L.M., Coffman R.L., Freedman A.S. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 2005, 105:489-495.
10. Gu J.Q., Wang D.F., Yan X.G., Zhong W.L., Zhang J., Fan B., Ikuyama S. A Toll-like receptor 9-mediated pathway stimulates perilipin 3 (TIP47) expression and induces lipid accumulation in macrophages. American Journal of Physiology, Endocrinology and Metabolism 2010, 299:E593-E600.
11. Hanada M., Delia D., Aiello A., Stadtmauer E., Reed J.C. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993, 82:1820-1828.
12. Hoshino R., Chatani Y., Yamori T., Tsuruo T., Oka H., Yoshida O., Shimada Y., Ari-i S., Wada H., Fujimoto J., Kohno M. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999, 18:813-822.
13. Houot R., Levy R. T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood 2009, 113:3546-3552.
14. Kater A.P., van Oers M.H., Kipps T.J. Cellular immune therapy for chronic lymphocytic leukemia. Blood 2007, 110:2811-2818.
15. Klinman D.M., Klaschik S., Sato T., Tross D. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Advanced Drug Delivery Reviews 2009, 61:248-255.
16. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nature Reviews Drug Discovery 2006, 5:471-484.
17. Lewis T.S., Shapiro P.S., Ahn N.G. Signal transduction through MAP kinase cascades. Advances in Cancer Research 1998, 74:49-139.
18. Li J., Song W., Czerwinski D.K., Varghese B., Uematsu S., Akira S., Krieg A.M., Levy R. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. Journal of Immunology 2007, 179:2493-2500.
19. Liang X., Moseman E.A., Farrar M.A., Bachanova V., Weisdorf D.J., Blazar B.R., Chen W. Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells. Blood 2010, 115:5041-5052.
20. Link B.K., Ballas Z.K., Weisdorf D., Wooldridge J.E., Bossler A.D., Shannon M., Rasmussen W.L., Krieg A.M., Weiner G.J. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. Journal of Immunotherapy 2006, 29:558-568.
21. Longo P.G., Laurenti L., Gobessi S., Petlickovski A., Pelosi M., Chiusolo P., Sica S., Leone G., Efremov D.G. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia 2007, 21:110-120.
22. Lu D., Zhao Y., Tawatao R., Cottam H.B., Sen M., Leoni L.M., Kipps T.J., Corr M., Carson D.A. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:3118-3123.
23. Moga E., Alvarez E., Canto E., Vidal S., Rodriguez-Sanchez J.L., Sierra J., Briones J. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma. Experimental Hematology 2008, 36:69-77.
24. Nicholson D.W., Ali A., Thornberry N.A., Vaillancourt J.P., Ding C.K., Gallant M., Gareau Y., Griffin P.R., Labelle M., Lazebnik Y.A., Munday N.A., Raju S.M., Smulson M.E., Yamin T.T., Yu V.L., Miller D.K. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995, 376:37-43.
25. Nilsson E.M., Brokken L.J., Harkonen P.L. Fibroblast growth factor 8 increases breast cancer cell growth by promoting cell cycle progression and by protecting against cell death. Experimental Cell Research 2010, 316:800-812.
26. Oliver F.J., de la Rubia G., Rolli V., Ruiz-Ruiz M.C., de Murcia G., Murcia J.M. Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis Lesson from an uncleavable mutant. Journal of Biological Chemistry 1998, 273:33533-33539.
27. Orrenius S. Mitochondrial regulation of apoptotic cell death. Toxicology Letters 2004, 149:19-23.
28. Pettitt A.R., Sherrington P.D., Stewart G., Cawley J.C., Taylor A.M., Stankovic T. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood 2001, 98:814-822.
29. Sebolt-Leopold J.S., Dudley D.T., Herrera R., Van Becelaere K., Wiland A., Gowan R.C., Tecle H., Barrett S.D., Bridges A., Przybranowski S., Leopold W.R., Saltiel A.R. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nature Medicine 1999, 5:810-816.
30. Slee E.A., Harte M.T., Kluck R.M., Wolf B.B., Casiano C.A., Newmeyer D.D., Wang H.G., Reed J.C., Nicholson D.W., Alnemri E.S., Green D.R., Martin S.J. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. Journal of Cell Biology 1999, 144:281-292.
31. Sun X.M., MacFarlane M., Zhuang J., Wolf B.B., Green D.R., Cohen G.M. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. Journal of Biological Chemistry 1999, 274:5053-5060.
32. Vollmer J., Krieg A.M. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Advanced Drug Delivery Reviews 2009, 61:195-204.
33. Weiner G.J. CpG oligodeoxynucleotide-based therapy of lymphoid malignancies. Advanced Drug Delivery Reviews 2009, 61:263-267.
34. Wierda W.G., Kipps T.J., Keating M.J. Novel immune-based treatment strategies for chronic lymphocytic leukemia. Journal of Clinical Oncology 2005, 23:6325-6332.
35. Wooldridge J.E., Weiner G.J. CpG DNA and cancer immunotherapy: orchestrating the antitumor immune response. Current Opinion in Oncology 2003, 15:440-445.
36. Wu Q.L., Buhtoiarov I.N., Sondel P.M., Rakhmilevich A.L., Ranheim E.A. Tumoricidal effects of activated macrophages in a mouse model of chronic lymphocytic leukemia. Journal of Immunology 2009, 182:6771-6778.